Life sciences business OptiBiotix Health plc (AIM: OPTI) has launched its SlimBiome-based GoFigure products on Amazon India, targeting the world's most populous nation and its growing consumer base.
India, with obesity rates at 40.3% and projected to have the largest medium-to-high income population by 2035, offers significant opportunities for weight management products.
GoFigure products will also remain available through Apollo Pharmacies, both in-store and online, as part of a multi-channel strategy to drive growth in high-potential markets. The Amazon launch coincides with a rebranding effort featuring more vibrant packaging and prominent Fossence branding, leveraging consumer trust in Tata's proprietary ingredient.
OptiBiotix, founded in 2012, develops microbiome-modifying compounds addressing obesity, cardiovascular health and diabetes. Its partnerships with over 20 global food and healthcare companies further enhance its position in the wellness market.
Inspiration Healthcare secures US purchasing agreement to drive Airon growth
West to sell SmartDose 3.5mL On-Body Delivery System rights to AbbVie for USD112.5m
Citius Pharmaceuticals reports full-year financial results
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS
Amgen announces Q1 2026 dividend
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera